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ABSTRACT
Background: Angiogenesis is one pathogenesis of allergic airway disease.
Methods: A potent angiogenic factor is platelet-derived endothelial cell growth factor (PD-ECGF), also known
as thymidine phosphorylase (TP) in the field of cancer-associated research. Vascular endothelial growth factor
(VEGF) is another representative angiogenic factor. Both factors were added to the culture system of human
peripheral blood mononuclear cells (PBMC) with IL-4 and anti-CD40 monoclonal antibody (mAb). Total IgE lev-
els in the supernatants and signal transduction of stimulated PBMC were evaluated.
Results: Addition of PD-ECGF enhances in vitro IgE production by PBMC in the presence of IL-4 and anti-
CD40 mAb, but VEGF does not enhance IgE production. Although PD-ECGF catalyzes the reversible phos-
phorolysis of thymidine to 2-deoxy-D-ribose-1-phosphate (2DDR), treatment of 2DDR has no effect on IgE pro-
duction by human PBMC. Both IL-4 and anti-CD40 mAb induce PD-ECGF by human PBMC. Thymidine phos-
phorylase inhibitor (TPI), 5-chloro-6-[1- (2-iminopyrrolidinyl) methyl] uracil hydrochloride reduce IgE production
via blocking of STAT6- phosphorylation.
Conclusions: Taken together, these results suggest TP involvement in the enhancement of IgE production
and suggest that TPI is a novel strategy against IgE-related allergic disease.
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INTRODUCTION
Neovascularization in exaggerated Th2 inflammation
and airway remodeling are cornerstones in the patho-
genesis of allergic airway disease.1 Increased vessel
number, vessel size, and vascular surface area con-
tribute to the severity of airway obstruction and air-
way hyper-responsiveness in patients with asthma.2
In allergic rhinitis, increased vessel number and per-
meability are also important features of nasal mu-
cosa.3,4
Vascular endothelial growth factor (VEGF) and
platelet-derived endothelial cell growth factor (PD-
ECGF) are representative critical regulators of angio-
genesis. In the pathogenesis of allergic rhinitis,
VEGF plays an important role: it increases vascular
permeability in a mouse model of allergic rhinitis.4
An elegant VEGF-transgenic mouse model demon-
strated that VEGF enhances respiratory antigen sen-
sitization, augments antigen-induced Th2 inflamma-
tion, increases the accumulation and activation of
dendritic cells, and serves a key role in antigen-
induced Th2 inflammation and cytokine elaboration.5
The expression level of VEGF in nasal biopsies of pa-
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tients with allergic rhinitis is about three times
higher than that of control, as determined using mi-
croarray analysis.6 Immunohistochemical analyses
have revealed that VEGF expression in endothelial
cells of nasal mucosa in patients with allergic rhinitis
is significantly higher than that in controls.7,8 Aller-
gen challenge to the nasal cavity increases the nasal
fluid VEGF concentration in patients with allergic
rhinitis.6
As an endothelial mitogen, PD-ECGF was isolated
from platelets.9 Expression of PD-ECGF is elevated in
many solid tumors and in chronically inflamed tis-
sues.10,11 Exaggerated PD-ECGF is associated with
nasal symptoms in allergic rhinitis.3 In fact, PD-ECGF
also has thymidine phosphorylase (TP) activity: TP
catalyzes the reversible conversion of thymidine to
thymine and 2-deoxy-D-ribose-1-phosphate (2DDR),
which is a powerful protein-glycating agent that gen-
erates oxygen radicals. Oxygen radicals increase the
angiogenic factors VEGF and IL-8.12 Consequently,
2DDR is necessary for the angiogenic effect of TP.
The level of TP activity in nasal mucosa from patients
with allergic rhinitis was significantly higher than
that from normal subjects.13
In fact, IgE is a crucial molecule for allergic rhini-
tis. Cross-linking of allergen-specific IgE bound to the
high affinity IgE receptor on the surface of mast cells
with multivalent allergens engenders the release of
both preformed and newly generated mediators, and
manifests nasal allergic symptoms. Although angio-
genic factors play an important role in allergic dis-
ease,14 the effect of angiogenic factor on IgE produc-
tion remains unclear. In this study, we investigated
whether two representative angiogenic factors
(VEGF and PD-ECGF) enhance in vitro IgE produc-
tion by human PBMC. Additionally, the effect of anti-
angiogenic factor on IgE production was examined.
METHODS
REAGENTS
Human IL-4 was a gift from Ono Pharmaceutical
(Osaka, Japan). Anti-CD40 mAb G28-5 and anti-
human IgE mAbs (CIA-E-7.12 and CIA-E-4.15) were
gifts from Dr. A. Saxon, University of California, Los
Angeles, CA, USA. Anti-human PD-ECGF mAb was a
gift from Dr. S. B. Fox, Christchurch School of Medi-
cine, Christchurch, New Zealand. An inhibitor of TP
(TPI), 5-chloro-6-[1-(2-iminopyrrolidinyl) methyl]
uracil hydrochloride (Ki = 2 × 10-8 M) was a gift re-
ceived from Taiho Pharmaceutical (Tokyo, Japan).
The following reagents were obtained commercially:
alkaline phosphatase-labeled goat anti-human IgE
(Kirkegaard & Perry Laboratories, Gaithersburg,
MD, USA), recombinant PD-ECGF (Leinco Tech-
nologies, St. Louis, MO, USA), 2DDR (Wako Pure
Chemical Industries, Osaka, Japan), VEGF (R&D
Systems, Minneapolis, MN, USA), mouse anti-human
IgG (Sigma Chemical, St. Louis, MO, USA), mouse
anti-human IgA (Sigma Chemical), alkaline phos-
phatase-labeled goat anti-human IgG Fab (Tago, Burl-
ingame, CA, USA), alkaline phosphatase-labeled goat
anti-human IgA (Tago), anti-PD-ECGF (R&D Sys-
tems), anti-STAT6 (R&D Systems), anti-phospho-
STAT6 (Y641) (R&D Systems), and anti-β-actin
(Sigma Chemical).
CELLS AND CELL CULTURES
Peripheral blood mononuclear cells (PBMC) were
isolated from healthy non-atopic volunteers using
Ficoll-Hypaque centrifugation. The PBMC (1 × 106
cellsml) were cultured in complete medium pre-
pared from RPMI supplemented with 2 mM of glu-
tamine, 100 unitsml of penicillin and 100 μgml of
streptomycin in the presence of IL-4 (100 unitsml)
and anti-CD40 mAb (0.1 μgml) for 7, 10, 14, and 21
days, which are optimal conditions for IgE produc-
tion.15,16 The IgD+ B cells were purified from PBMC
using naive B Cell Isolation Kit II in a MACS system
(Miltenyi Biotec, Tokyo, Japan). Isolated B cells were
cultured in the same conditions as those for PBMC.
Ig MEASUREMENTS
Total IgE, IgA and IgG levels in the supernatants of
stimulated cells were measured using ELISA, as de-
scribed previously.15,16 Briefly, microtiter plates were
coated overnight at 4℃ with mAb of two types to anti-
human IgE (CIA-E-7.12 and CIA-E-4.15), or anti-
human IgA, or anti-human IgG. After the wells were
blocked with 0.1% gelatin for at least 1 hr, 100 μl of
culture supernatants were plated in duplicate wells.
Then the plates were incubated for 2 hr at room tem-
perature. After washing, alkaline phosphatase-labeled
IgE or IgA or IgG was added for detection. Absor-
bance at 405 nm was read using an ELISA reader
(Bio-Tek Instruments, Burlingame, CA, USA). The
sensitivity of the assay for the IgE subclasses was 0.1
ngml.
RNA EXTRACTION, RT-PCR, REAL-TIME PCR
STRATEGY
Total mRNA was obtained from stimulated and non-
stimulated human PBMC using a total RNA isolation
kit (NucleoSpinTM RNA II; Machery-Nagel, Duren,
Germany). Total RNA (0.5 μg) was reverse-
transcribed to cDNA using a first-strand cDNA syn-
thesis kit (GE Healthcare Japan, Tokyo, Japan) under
conditions recommended by the manufacturer.
For this study, PCR assays were conducted in 50-μl
reactions containing 50 mM KCl, 20 mM Tris-HCl
(pH 8.4), 2.5 mM MgCl2, 5% DMSO, 50 pM primer
reaction, and 2.5 U of Taq polymerase. For detection
of PD-ECGF, PCR was conducted using 40 cycles of
94℃ for 1 min, 65℃ for 1 min and 72℃ for 1 min.
Primers for PD-ECGF were 5’-GCTTCGTGGCCGCT
GTGGTG-3’ and 5’-TCTGCTCTGGGCTCTGGATGA-
3’.17,18 Primers for the ε-germline transcript were 5’-A
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Fig.　1　Effects of VEGF and PD-ECGF on IgE production 
by PBMC. Human PBMC from non-atopic healthy donors
(n = 7) was cultured with IL-4 and anti-CD40 mAb for 10 days 
with various concentrations of VEGF or PD-ECGF. Data 
were expressed as mean ± SEM (*P < 0.05; **P < 0.01 com-
pared with IgE values for stimulation with IL-4 plus anti-CD40 
mAb in the absence of PD-ECGF).
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GGCTCCACTGCCCGGCACAGAAATA-3’ and 5’-GG
ACAAGTCCACGTCCATGA-3.19
The respective amplifications of suppressors of cy-
tokine signaling 1 (SOCS1), SOCS3, SOCS5 and β2-
microglobulin-cDNA were performed in a MicroAmp
optical 96-well reaction plate (Applied Biosystems,
Branchburg, NJ, USA). All TaqMan probe-primer
combinations assay product and Applied Biosystems
products were used for this study. Real-time PCR was
conducted under conditions recommended by the
manufacturer. The threshold cycle number (Ct) was
determined using sequence detector software (ver.
1.1, Applied Biosystems) and transformed using Ct
methods, as described by the manufacturer, with β2-
microglobulin as the calibrator gene.
WESTERN BLOT
The PBMC were boiled with electrophoresis sample
buffer for 3 min and separated using 12.5% SDS-
PAGE. The separated proteins were transferred elec-
trophoretically to polyvinylidene difluoride mem-
branes at the same protein concentration per lane.
The membranes were blocked at room temperature
for 1 h in pH 7.4 PBS with 10% BSA. They were then
probed with Ab, as described previously.20,21 Band
quantities of PD-ECGF expression of PBMC were
analyzed from findings of immunoblotting using a Bio
Image System (Genomic Solutions, Ann Arbor, MI,
USA).
IMMUNOPRECIPITATION
Cells were collected by centrifugation and lysed in tri-
ton buffer. The lysate was clarified and incubated
with excess protein A-Sepharose 4B. The clarified
sample was immunoprecipitated with Ab and protein
A-Sepharose 4B at 4℃.20,21 The immune complexes
were then processed for immunoblotting as de-
scribed above.
STATISTICS
Data were expressed as mean ± SEM. The statistical
significance of effects on Ig production was deter-
mined using the Wilcoxon signed rank test.
RESULTS
PD-ECGF ENHANCED IgE PRODUCTION, BUT
NOT VEGF
The basal level of IgE from PBMC for 10 days culture
without IL-4 and anti-CD40 mAb was under the limit
of ELISA (<0.1 ngml). The culture of PBMC with IL-
4 and anti-CD40 mAb induced IgE for 10 days
(119.4 ± 8.1 ngml). Then PBMC was cultured for 10
days with IL-4 and anti-CD40 mAb in various concen-
trations of recombinant VEGF and recombinant PD-
ECGF. As Figure 1 shows, VEGF did not induce en-
hancement of IgE production significantly in any of
seven independent preparations of PBMC. Actually,
VEGF did not enhance IgE production between day 7
and day 21 (data not shown).
The PD-ECGF enhanced the production of IgE in-
duced by IL-4 plus anti-CD40 mAb in a bell-shaped
pattern (Fig. 1). The maximum effect of PD-ECGF on
increased IgE production was obtained at concentra-
tions of 1 ngml in seven independent preparations of
PBMC. The PD-ECGF (1 ngml) enhanced produc-
tion of IgE (154.2% compared to control, P < 0.01) by
IL-4 plus anti-CD40 mAb without affecting production
of IgA (98.5% compared to control). The PD-ECGF (1
ngml) also enhanced production of IgG (140.9%
compared to control, P < 0.05) by IL-4 plus anti-CD40
mAb. Neither VEGF nor PD-ECGF showed any effect
on the viability or cell number of PBMC, as shown by
trypan blue dye exclusion (data not shown). Actually,
PD-ECGF had no effect on cell proliferation of the
PBMC cells by deterrence of MTT assay (data not
shown).
When purified B cells were cultured with IL-4 and
anti-CD40 mAb in the presence of PD-ECGF (1 ng
ml), production of IgE was slightly greater than that
in the absence of PD-ECGF (Fig. 2). However, no sig-
nificant difference was found between the two
groups. VEGF did not enhance IgE production by IL-
4 plus anti-CD40 mAb in purified B cells (Fig. 2).
2DDR HAD NO EFFECT OF IgE PRODUCTION
The PD-ECGF has thymidine phosphorylase, which
catalyzes the reversible phosphorolysis of thymidine
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Fig.　2　Effect of VEGF and PD-ECGF on IgE production by
B cells. Human purified B from non-atopic healthy donors
(n = 5) was cultured with IL-4 and anti-CD40 mAb for 10 days 
with various concentrations of VEGF or PD-ECGF. Data 
were expressed as mean ± SEM.
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Fig.　3　PD-ECGF expression by PBMC. a) PBMC from non-
atopic healthy donors was cultured with or without IL-4 and
anti-CD40 mAb for 24 hr and RT-PCR was conducted. With 
AF-10 cells, the B cell line was the positive control for PD-
ECGF mRNA expression. b) PBMC from non-atopic healthy
donors were cultured with or without IL-4 and anti-CD40
mAb for 3 days. Then PD-ECGF protein expression was ex-
amined using Western blotting. The PD-ECGF added to the 
culture system and the culture medium were used as positive
controls.
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to 2DDR, but which itself has angiogenic activity.12
We added various concentrations of 2DDR to the cul-
ture system to confirm that angiogenic activity is in-
volved with IgE production enhancement by human
PBMC. Each addition of 2DDR (0.01-100 ngml)
showed no effect on IgE production induced by IL-4
plus anti-CD40 mAb (98.3-105.0% compared to con-
trol), which suggests that the angiogenic activity
caused no direct enhancement of IgE production.
CELL ACTIVATION
It is assumed that PD-ECGF and TP are identical.
Tumor-infiltrating macrophages frequently show
overexpression of TP, which has been reported to in-
dicate a potential role in increased tumor activity.10
The level of TP activity in nasal mucosa from patients
with allergic rhinitis was significantly higher than
that from normal subjects.13 To investigate the
mechanism of PD-ECGF mediated enhancement of
IgE production by human PBMC, the expression of
TP in human PBMC was examined. As Figure 3a
shows, stimulation of IL-4 and anti-CD40 mAb in-
duced messenger RNA (mRNA) expression of PD-
ECGF in all of three independent PBMC. Non-
stimulated PBMC showed no expression of PD-
ECGF mRNA. The AF-10, B cell lines were used as a
positive control expressing PD-ECGF mRNA. Non-
stimulated purified B cells showed no expression of
PD-ECGF. Stimulation of IL-4 and anti-CD40 mAb
also induces a weak band of PD-ECGF expression in
purified B cells (data not shown).
Western blot analysis also showed that both IL-4
and anti-CD40 mAb induced PD-ECGF protein ex-
pression in PBMC (Fig. 3b). Spontaneous PD-ECGF
protein expression was not shown in PBMC. A cul-
ture system with added PD-ECGF was used as a posi-
tive control.
PD-ECGF DID NOT AFFECT IgE CLASS SWITCH-
ING
The Ig isotype switching is preceded by germ-line
transcription from the heavy chain locus that will sub-
sequently undergo switch recombination.19 To assess
the induction of ε-germline transcript by PD-ECGF, a
RT-PCR strategy was undertaken with IgD+ B cells.
Stimulation of IL-4 induced ε-germline transcript by
IgD+ B cells. PD-ECGF did not induce ε-germline
transcription by IgD+ B cells (data not shown). This
result demonstrates that PD-ECGF is not a switch fac-
tor for IgE.
THYMIDINE PHOSPHORYLASE INHIBITOR (TPI)
An extremely potent TPI22 was generated in Japan.
Figure 3 portrays that TPI inhibited mRNA expres-
sion of PD-ECGF. Actually, TPI has been shown to in-
hibit TP completely in vitro with a Ki value of 20 μM
without affecting other enzymes.23 As Figure 4
shows, the addition of TPI reduced IgE production by
PD-ECGF Enhanced Human IgE Production
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Fig.　4　Effect of TPI on IgE production. Human PBMC from 
non-atopic healthy donors (n = 6) was cultured with IL-4 and 
anti-CD40 mAb for 10 days with various concentrations of 
TPI. *p < 0.05; **p < 0.01 compared with IgE values for stim-
ulation with IL-4 plus anti-CD40 mAb in the absence of TPI.
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Fig.　5　TPI blocked STAT6 phosphorylation of B cells.
Human purified B cells were stimulated with IL-4 and anti-
CD40 in the absence or presence of PD-ECGF/TPI for 3 hr
and harvested. The sample was immunoprecipitaed using 
anti-phospotyrosine Ab and blotted with anti-STAT6 Ab. The
same amount of lysate as that before immunoprecipitation 
was applied to each lane and blotted with anti-STAT6 Ab.
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PBMC stimulated with IL-4 and anti-CD40 mAb dose-
dependently. In all six dependent experiments, at
least 31.3 μM TPI significantly inhibited IgE produc-
tion by PBMC (67.8% compared to control, P < 0.05)
without affecting production of IgA (89.5% compared
to control). The same concentration of TPI also inhib-
ited IgG production by PBMC (70.5% compared to
control, P < 0.05). Cell viability was unaffected by the
treatment of 500 μM TPI (data not shown).
INHIBITION MECHANISM OF TPI ON IgE PRO-
DUCTION
The signal transducer and activator of transcription 6
(STAT6) is an obligatory transcription factor in IL-4
signaling. To analyze whether STAT6 plays a role in
regulating IgE production in response to TPI, an-
tiphosphotyrosine immunoprecipitates of cell lysates
from B cells treated with or without TPI were sub-
jected to immunoblotting with anti STAT6 Ab. Stimu-
lation of IL-4 and anti-CD40 triggered rapid and sus-
tained phosphorylation of STAT6 (Fig. 5). Addition of
PD-ECGF enhanced phosphorylation of STAT6. How-
ever, the exposure of IL-4 and anti-CD40 stimulated B
cells to TPI blocked the phosphorylation of STAT6,
but not expression of STAT6.
DISCUSSION
Results of this study demonstrate that PD-ECGF
thymidine phosphorylase (TP) enhanced IgE produc-
tion in vitro by PBMC stimulated with IL-4 plus anti-
CD40 mAb. The angiogenic factors 2DDR (a degra-
dation product of thymidine generated by TP enzy-
matic activity) and VEGF showed no effect on IgE
production. Stimulation with IL-4 plus anti-CD40 mAb
induced mRNA and the protein of TP in PBMC. The
treatment of TPI inhibited the IgE production in vitro
by PBMC that had been stimulated with IL-4 plus
anti-CD40 mAb. The exposure of TPI blocked phos-
phorylation of STAT6, which was induced by IL-4 and
anti-CD40 mAb stimulation. These results suggest
that TP is an influential factor on IgE production in vi-
tro by a human peripheral blood system.
The PD-ECGFTP was found in platelet lysate. It is
reportedly a classic growth factor that binds its cell
receptor to exert angiogenic activity.9 In carcinoma
cell lines, TP inhibits hypoxia-induced apoptosis via
blocking of the activation of p38 mitogen-activated
protein kinase (MAPK) but not C-Jun N-terminal
kinase (JNK).24 However, p38 MAPK is necessary for
CD40-mediated class switching to IgE in human B
cells.25 Reportedly, B lymphocyte stimulator activates
p38 MAPK in human Ig class switch recombination.26
For that reason, we inferred at the outset of this re-
search that TP might be a candidate of IgE class
switching inhibitor via blocking of p38MAPK. Never-
theless, results show that TP enhanced IgE produc-
tion by PBMC.
IL-4 binds the IL-4 receptor (IL-4R) α subunit. The
IL-4Rα chain, which is phosphorylated by Jak3, binds
to STAT6 via interaction between the phosphotyro-
sine motif and Src homology 2 domain of STAT6.27
Subsequently, STAT6 itself is phosphorylated by Jak1
and homodimerizes. The dimeric form translocates to
the nucleus where it binds to IL-4 response elements,
initiating transcription of IgE gene.28 Consequently,
STAT 6 is necessary for IgE class switch recombina-
tion. The TPI blocked IL-4 plus anti-CD40 induced
STAT6 phosphorylation in B cells. Suppressor of cy-
tokine signaling (SOCS) 5, which is expressed pre-
dominantly in Th1 cell, inhibits the IL-4-mediated
Yamamoto H et al.
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STAT6 activation.29 Furthermore, IFNγ induces
SOCS1 in a STAT1-dependent manner,30 SOCS1 in-
hibits STAT6 phosphorylation, and TPI did not in-
duce SOCS5 and SOCS1 in B cells in our experi-
ments (data not shown). Therefore, nucleic acid me-
tabolism in cells or unknown factors might be in-
volved in suppression of STAT6-phosphorylation.
Further studies must be undertaken to address this
important point.
Earlier studies showed TP expression to be
upregulated by various inflammatory cytokines of
monocyte and macrophage origin such as IL-1β,
TNFα, and IFNγ. This inflammation-mediated
upregulation of TP might provide favorable condi-
tions for angiogenesis and malignancy of human tu-
mors.31 The infection of nasal mucosa by viruses and
bacteria releases IL-1β and TNFα from epithelial
cells, fibroblasts, and basal cells. Reportedly, several
cells of mucosal epithelium have high TP in normal
tissues such as fibroblast and basal cells.32 Conse-
quently, the released IL-1β and TNFα might enhance
TP-production of monocytes and macrophages, fibro-
blasts, and basal cells by the autocrine system. In-
creased TP might enhance IgE production to anti-
gens in nasal mucosa because we demonstrated local
IgE class switching and local IgE syntheses in human
allergic nasal mucosa.15 This speculation might en-
gender clinical worsening of allergic symptoms by
mild virus infection in patients with allergic rhinitis.
Certainly, PD-ECGFTP is not a class switch factor
for IgE because PD-ECGF did not induce ε-germline
transcript. Perhaps PD-ECGFTP reinforces the sig-
nals of IL-4 plus anti-CD40 mAb. We demonstrated in
an earlier study that IL-4 plus anti-CD40 mAb induces
Ig isotype switch for μ to γ1, γ3, and γ4.33 The result
that PD-ECGF enhanced IgG production by IL-4 plus
anti-CD40 mAb is consistent with that result. When
PD-ECGF is added to the PBMC culture system in
the absence of IL-4 plus anti-CD40 mAb, IgG produc-
tion was not increased (data not shown).
Although VEGF has been demonstrated to serve
an important role in the pathogenesis of allergic rhini-
tis4, VEGF itself apparently has no effect on IgE pro-
duction in vitro in this experiment. Clinical data also
show a nonsignificant correlation between serum IgE
and sputum VEGF in asthmatic children.34
As a potent antiangiogenic factor, endostatin pre-
vented the development of asthma in one study using
a mouse model.35 Treatment with endostatin inhibits
the airway hyperresponsiveness, pulmonary allergic
inflammation, production of antigen-specific IgE, and
lung inflammatory mediators in VEGF-dependent and
VEGF-independent mechanisms. Antiangiogenesis
therapy by antiangiogenic medicine reportedly re-
duces asthma symptoms in patients with rheumatoid
arthritis and moderately severe asthma.36 A new anti-
tumor drug, TAS102, is combined for TPI and cyto-
toxic pyrimidine analog for patients with cancer. Cur-
rently, TAS102 is being evaluated in phase I studies
as an oral formulation.37 Results of this study and evi-
dence from the literature suggest that TPI is an effec-
tive new method of inducing protection against IgE-
related allergic disease.
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